Source - LSE Regulatory
RNS Number : 6375U
Bridgepoint Group plc
01 July 2024
Bridgepoint Group plc
("Bridgepoint" or the "Company")
Director Declaration
In accordance with Listing Rule 9.6.14R, the Company advises that Cyrus Taraporevala, an Independent Non-Executive Director, has been appointed as a Non-Executive Director of Pfizer Inc.
ENQUIRIES:
Bridgepoint
Analysts and investors Adam Key +44 7833 748010
| Media Christian Jones / James Murray christian.jones@bridgepoint.eu james.murray@bridgepoint.eu +44 20 7034 3500 |
FGS Global (Public Relations Adviser to Bridgepoint)
Charles O'Brien / +44 20 7251 3801 / +44 7825 043 656
Anjali Unnikrishnan / +44 20 7251 3801 / +44 7826 534 233
Legal Entity Identifier (LEI): 213800KFNMVI8PDZX472
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.